Sergio J. Azevedo
Porto Alegre, RS, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Journal: Journal of hepatology
Published: February 16, 2024
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Journal: Future oncology (London, England)
Published: September 06, 2023
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: October 12, 2022
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Journal: NEJM evidence
Published: August 01, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Journal: European urology
Published: December 03, 2021
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: December 11, 2020
Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: November 10, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 08, 2020
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Journal: The New England journal of medicine
Published: February 20, 2019
Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
Journal: JAMA oncology
Published: March 23, 2018
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Journal: The oncologist
Published: December 07, 2016
"Burnout in Medical Oncology Fellows: a Prospective Multicenter Cohort Study in Brazilian Institutions".
Journal: Journal of cancer education : the official journal of the American Association for Cancer Education
Published: May 09, 2015
Last Updated: 09/26/2026